DOCSLIB.ORG

Speed with Vision

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Speed with Vision Yamanouchi Pharmaceutical Co., Ltd. Yamanouchi Speed with Vision Annual Report 2001 Yamanouchi Pharmaceutical Co., Ltd. Annual Report 2001 d paper 01.9.18, 0:00 PM Adobe PageMaker 6.5J/PPC SPEED WITH VISION — Move quickly in preparation, implementation and achievement of goals — Corporate philosophy: “Creating and Caring ... for Life” — Products that contribute to the well-being of people everywhere Goal: Become a Market-Oriented, R&D-Driven Global Enterprise In Pursuit of Future Prosperity Accelerate global clinical development Start our own sales activities in the U.S. and turn profitable quickly Bolster genomics discovery research Growing Profits Expand sales of mainstay products and quickly launch new products Raising Corporate Value Aim for sustainable growth Raise management transparency Uphold the highest ethical standards Raise employee motivation Cautionary Statement Regarding Forward-Looking Information This annual report includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to manage- ment and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regula- tory developments, delays in new product launches, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company’s intellec- tual property rights and the adverse outcome of material litigation. CONTENTS Gastrointe Gaster® Gaster® D YM643 (int Cardiovasc Lipitor® Dorner® Financial Highlights p1 Perdipine® ® Message from the Management p2 Perdipine Hypoca® Business Approach in the United States p7 CHOLEBIN Frandol® Milrila® Pronon® Special Feature Solinase® YM087 (co YM028 Urology Harnal® YM152 (fin YM905 YM598 ® ® ® Harnal p10 Lipitor p12 Gaster p14 Genomics Consumer Neurology Discovery Products Dormicum® Research p16 Businesses p18 Solinase® YM992 YM872 YM337 Corporate Citizenship p21 Diabetes Environmental Protection p22 Starsis® ® Board of Directors p23 Euglucon Financial Section p24 Locomotor Bisphonal® Principal Subsidiaries and Affiliates p55 Corporate Data and Affiliates/Corporate Information p56 YM484 Stock Price Information/Common Stock p57 YM177 (ce Oncology Nasea® YM294 (op YM529 (mi YM511 Other Josamycin Farom® Optiray® YM454 Nasanyl® YM670 (mu gelatine pa Notes: 1. * additiona 2. ** additiona 3. Drug candi 名称未設定-2 Page 2 MAIN PRODUCTS AND PIPELINE ST Indications Classification Status Gastrointestinal Indications Classification Status ® Gaster Peptic ulcers, gastritis H2 antagonist Launched (Japan/Asia) Year ® Gaster D Peptic ulcers, gastritis H2 antagonist (orally disintegrating tablet) Launched (Japan) Com YM643 (interferon alfacon-1) Chronic hepatitis C Consensus interferon (CIFN) Launched (Europe) H Filed (Japan) Lo Cardiovascular Av Lipitor® Hypercholesterolemia HMG-CoA reductase inhibitor Launched (Japan) Ye ® Dorner Chronic arterial occlusion PGI2 derivative Launched (Japan/Asia) Perdipine® Hypertension Ca antagonist Launched (Japan/Asia/Europe) ® Perdipine LA Hypertension Ca antagonist (long acting) Launched (Japan/Asia) Aver Hypoca® Hypertension Ca antagonist (once daily) Launched (Japan/Asia/Europe) CHOLEBINE® Hypercholesterolemia Nonabsorbable anion exchange regin Launched (Japan) Frandol® Angina pectoris Coronary artery dilator Launched (Japan) 6,00 Milrila® Acute heart failure Phosphodiesterase III inhibitor Launched (Japan) Pronon® Arrhythmia Na channel inhibitor Launched (Japan) Solinase® Acute myocardial infarction Modified t-PA Launched (Japan) 5,00 YM087 (conivaptan) Hyponatremia, heart failure Vasopressin antagonist P-III/II (Japan/Europe/USA) YM028 Thrombosis GPIIb/IIIa antagonist P-II (Japan) 4,00 Urology ® Harnal Functional symptoms of benign prostatic hyperplasia Alpha 1 receptor antagonist Launched (Japan/Asia/Europe) 3,00 Lower urinary tract symptoms* Alpha 1 receptor antagonist P-III (Japan) Functional symptoms of benign prostatic hyperplasia Alpha 1 receptor antagonist (TOCAS)** P-II (Europe) 2,00 YM152 (finasteride) Benign prostatic hyperplasia 5 alpha-reductase inhibitor Filed (Japan) YM905 Urinary frequency, urinary urgency and incontinence Muscarinic M3 antagonist P-III (Europe/USA) 1,00 YM598 Advanced prostate cancer Endothelin ETA antagonist P-II (Europe/USA) Neurology Dormicum® Sedation, anxiolysis and amnesia Short-acting benzodiazepine CNS depressant Launched (Japan) Solinase® Acute ischemic stroke* Modified t-PA P-II (Japan) YM992 Depression Selective 5-HT reuptake inhibitor and noradrenaline P-II (Europe/USA) augmenting 5HT2A antagonist (SINAS) CO YM872 Acute ischemic stroke AMPA antagonist P-II (Europe/USA) YM337 Acute ischemic stroke, high-risk PTCA GPIIb/IIIa antagonist (monoclonal antibody) P-II (Europe/USA) Diabetes As o Starsis® Diabetes Insulin secretion enhancer Launched (Japan) Euglucon® Diabetes Sulfonylureas Launched (Japan) Num out Locomotorium/Inflammation Bisphonal® Hypercalcemia Bisphosphonate Launched (Japan) Osteoporosis* Bisphosphonate Filed (Japan) Periodontitis* Bisphosphonate P-II (Japan) As o YM484 Open long bone fracture (Europe) Bone morphogenetic protein-2 (rhBMP-2) Filed (Europe) Mar Promotion of bone formation (Japan) Bone morphogenetic protein-2 (rhBMP-2) P-III (Japan) YM177 (celecoxib) Rheumatoid arthritis, osteoarthritis Cyclooxygenase-2 inhibitor P-III (Japan) Note Oncology ® Nasea Emesis due to chemotherapy 5HT3 antagonist Launched (Japan/Asia) As o YM294 (oprelvekin) Prevention of chemotherapy-induced thrombocytopenia Thrombocytopoietic factor (rhIL-11) P-III (Japan) YM529 (minodronate) Multiple myeloma, bone metastasis with breast/lung cancer Bisphosphonate P-III (Japan) Prin YM511 Breast cancer, endometriosis, uterine myoma Aromatase inhibitor P-II (Japan/Europe) St N Other Th ® Josamycin Infections Macrolide antibiotic Launched (Japan/Asia/Europe) Th Farom® Infections Penam-type antibiotic Launched (Japan) Ja Optiray® Contrast medium Non-ionic contrast medium Launched (Japan) YM454 Contrast medium Ultrasound contrast agent Filed (Japan) Num Nasanyl® Endometriosis GnRH agonist Launched (Japan) YM670 (multiporous Transcatheter arterial embolization therapy Arterio-embolization particles P-III (Japan) Tran gelatine particles) Notes: 1. * additional indication 2. ** additional formulation 3. Drug candidates under development that are listed above exclude those in Phase I or preclinical stages. 01.9.18, 0:01 PM Adobe PageMaker 6.5J/PPC FINANCIAL HIGHLIGHTS Yamanouchi Pharmaceutical Co., Ltd. and Consolidated Subsidiaries Years ended March 31, 2001, 2000, 1999, 1998 and 1997 Millions of yen 2001 2000 1999 1998 1997 Net sales . ¥457,913 ¥433,653 ¥423,217 ¥477,356 ¥454,740 Operating income . 97,844 96,069 89,445 102,845 101,229 Net income . 40,341 57,175 48,002 6,092 41,866 Total assets . 896,280 829,286 776,031 802,735 831,899 Shareholders’ equity, net . 677,713 620,221 549,972 507,535 473,199 Research and development expenses . 54,567 54,821 54,299 43,639 42,309 Capital expenditures . 36,828 29,831 51,405 57,575 36,112 Depreciation . 30,804 23,460 29,338 18,454 12,748 Yen Per share: Net income: Basic . ¥ 111.80 ¥ 162.35 ¥ 140.79 ¥ 18.18 ¥ 129.12 Diluted . 109.95 155.97 129.21 17.51 116.56 Shareholders’ equity . 1,876.54 1,721.77 1,596.65 1,498.91 1,459.15 Cash dividends applicable to the year . 25.00 25.00 23.00 25.00 25.00 Notes: 1. Effective April 1, 1999, the Company changed its method of accounting for retirement benefits to recognizing the liability for retirement benefits at the present value of the estimated retirement benefits to be paid upon the future termination of its employees’ services, less the balance of the plan assets at fair value.The effect of this change was to increase operating income by ¥573 million and to decrease income before income taxes and minority interests by ¥12,587 million for the year ended March 31, 2000. 2. Effective April 1, 1997, the Company changed its methods of accounting for the excess of cost over net assets acquired and for income taxes. The effect of the change in the accounting for the excess of cost over net assets acquired was to increase the amortization of the excess of the cost over net assets acquired by ¥72,730 million and to decrease net income by the same amount for the year ended March 31, 1998. Also, the effect of the change in the accounting for income taxes was to decrease the income tax expense by ¥24,477 million and to increase net income by the same amount for the year ended March 31, 1998. 3. Due to a change effective the year ended March 31, 2000 in the regulations relating to the presentation of translation adjustments, the Company has presented translation adjustments as a component of shareholders’ equity instead of as a component of assets or liabilities. Accordingly, the amounts for 1999, 1998 and 1997 were restated in the above table. 4. A new accounting standard for financial instruments, which became effective on April 1, 2000, requires that securities be classified into three categories; trading, held-to-maturity or other securities. Under the new standard, trading securities are carried at fair value and held-to-maturity securities are carried at amortized cost. Marketable securities classified as other securities are carried at fair value with changes in unrealized gain or loss, net of the applicable income taxes, directly included in shareholders’
Load more

Recommended publications
  • Histamine Receptors
    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
    [Show full text]
  • Etiology, Classification, and Treatment of Urticaria
    CONTINUING MEDICAL EDUCATION Etiology, Classification, and Treatment of Urticaria Kjetil Kristoffer Guldbakke, MD; Amor Khachemoune, MD, CWS GOAL To understand urticaria to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Discuss the clinical classification of urticaria. 2. Recognize how to diagnose urticaria. 3. Identify treatment options. CME Test on page 50. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. December 2006. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 CreditTM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Drs. Guldbakke and Khachemoune report no conflict of interest. The authors discuss off-label use of colchi- cine, cyclophosphamide, cyclosporine, dapsone, intravenous immunoglobulin, methotrexate, montelukast sodium, nifedipine, plasmapheresis, rofecoxib, sulfasalazine, tacrolimus, thyroxine, and zafirlukast. Dr. Fisher reports no conflict of interest. Urticaria is among the most common skin dis- autoimmune mechanisms are now recognized as a eases. It can be acute, chronic, mediated by a cause of chronic urticaria. A search of the PubMed physical stimulus, or related to contact with an database (US National Library of Medicine) for urticant.
    [Show full text]
  • Receptor Antagonist
    Gut: first published as 10.1136/gut.29.7.890 on 1 July 1988. Downloaded from Gut, 1988, 29, 890-893 Alteration of H2 receptor sensitivity in duodenal ulcer patients after maintenance treatment with an H2 receptor antagonist D B JONES, C W HOWDEN, D W BURGET, CINDY SILLETTI, AND R H HUNT From the Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, Canada SUMMARY The effects of a specific H2 receptor agonist impromidine, on gastric acid secretion were measured in six patients with duodenal ulcer in clinical remission before and after three months treatment with ranitidine 150 mg nocte. After treatment basal acid output increased from 1 2 to 2-8 mmol/h and after maximal impromidine stimulation from 36-9 (4 7) to 44-2 (6 2) mmol/h (p<002). Intravenous ranitidine 50 mg was given at the end ofthe impromidine infusion on each study day; the antisecretory effect of intravenous ranitidine was accentuated after the treatment with ranitidine from a trough acid output of8 5 (1-2) mmol/h before, to 3-8 (1-5) mmol/h (p<0 05) after, treatment. The increased response to the H2 agonist impromidine and the H2 antagonist ranitidine after treatment with ranitidine suggests an enhanced sensitivity of the H2 receptor. This might be ex- plained on the basis of an increase in the number of H2 receptors ('up-regulation'). http://gut.bmj.com/ The discovery of the histamine H2 receptor on the a highly potent, and specific agonist for the H2 parietal cell' initiated the development of H2 receptor' exhibiting up to 27 times the affinity of receptor antagonists with potent gastric antisecretory histamine.9 In this study we have examined the effect activity and these agents have now become firmly of three months of treatment with ranitidine 150 mg established in the treatment of peptic ulceration.- nocte on impromidine stimulated gastric acid secre- After heaing of duodenal ulcer by the H2 receptor tion in six patients with duodenal ulcer in remission.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]
  • Guidance on the Use of H2 Antagonists for the Prevention and Management of Hypersensitivity
    Guidance on the use of H2 antagonists for the prevention and management of hypersensitivity To guide for members on the prevention and management of hypersensitivity in situations where H2 antagonists are in short supply or unavailable www.bopa.org.uk Version 1.0 3rd June 2020 Contents 1. Scope ........................................................................................................................................ 3 2. Introduction ................................................................................................................................ 3 3. Approach ................................................................................................................................... 3 4. Guidance ................................................................................................................................... 4 5. Table 1: H2 Antagonists ............................................................................................................. 6 6. References ................................................................................................................................ 7 7. Acknowledgements ................................................................................................................... 8 8. Document control ...................................................................................................................... 8 Guidance on the use of H2 antagonists for the prevention and management of hypersensitivity Page 2 of 8 1. Scope 1.1 This guidance
    [Show full text]
  • Histamine H2 Antagonist (Oral Route, Injection Route, Intravenous Route)
    Histamine H2 Antagonist (Oralvisited Route, Injectionon 8/21/2015 Route, Intravenous Route)... Page 1 of 7 Request an Appointment Log in to Patient Search Mayo Clinic Find a Doctor Account Find a Job Translated Content Give Now PATIENT CARE & DEPARTMENTS & RESEARCH EDUCATION FOR MEDICAL PRODUCTS & GIVING TO HEALTH INFO CENTERS PROFESSIONALS SERVICES MAYO CLINIC Drugs and Supplements Print Histamine H2 Antagonist (Oral Route, Injection Route, Intravenous Route) Proper Use Advertisement Description and Brand Names Drug information provided by: Micromedex Before Using For patients taking the nonprescription strengths of these Proper Use medicines for heartburn, acid indigestion, and sour stomach: Precautions • Do not take the maximum daily dosage continuously for more than 2 weeks, unless directed to do so by your doctor. Side Effects • If you have trouble in swallowing, or persistent abdominal pain, see your doctor promptly. These may be signs of a Products and services serious condition that may need different treatment. For patients taking the prescription strengths of these medicines for more serious problems: • One dose a day—Take it at bedtime, unless otherwise Mayo Clinic is a not-for-profit organization. directed. Proceeds from website advertising help • Two doses a day—Take one in the morning and one at support our mission. Mayo Clinic does not endorse non-Mayo products and services. bedtime. • Several doses a day—Take them with meals and at bedtime Advertising & Sponsorship for best results. Policy Opportunities It may take several days before this medicine begins to relieve stomach pain. To help relieve this pain, antacids may be taken Mayo Clinic Store with the H2-blocker, unless your doctor has told you not to use them.
    [Show full text]
  • Resistant Duodenal Ulcer: When, Why and What to Do?
    Postgraduate Medical Journal (1988) 64, 369-372 Postgrad Med J: first published as 10.1136/pgmj.64.751.369 on 1 May 1988. Downloaded from Difficult Decisions Resistant duodenal ulcer: when, why and what to do? R.P. Walt' and T.K. Daneshmend2 'Department of Medicine, Queen Elizabeth Hospital, Birmingham BJ5 2TH and 2Department of Therapeutics, Queen's Medical Centre, Nottingham NG7 2UH, UK. Introduction Duodenal ulceration is a chronic disease the causes Many people include ulcer relapse as evidence of of which remain unknown. Current medical treatment failure or resistance. Unfortunately treatment interrupts the natural history and relapse of duodenal ulcer is even less well accelerates ulcer healing. It does not cure ulcers. All understood and available data do not allow us to duodenal ulcers are generally considered together distinguish between expected and unexpected even though pathophysiological mechanisms differ relapse.6 A recent study has shown that asympto- from patient to patient. It should not be surprising matic relapse and subsequent healing are common that some duodenal ulcer patients respond relatively during maintenance and that most maintenance poorly. However, duodenal ulcers which do not trials have probably underestimated true ulcer heal in the 'usual' time have traditionally been recurrence by nearly half.7 There is also an unsub- labelled as difficult, refractory, intractable, stantiated belief that most ulcers which recur within copyright. stubborn, recalcitrant, persistent, or resistant. There a few days of stopping treatment had never really is no agreement on the definition of resistance and healed and were missed by endoscopists. For these such patients may merely represent one extreme of reasons we will not consider failure of long-term the 'normal' ulcer population.
    [Show full text]
  • Drug Treatment of Peptic Ulcer Disease Bali A
    SMGr up Drug Treatment of Peptic Ulcer Disease Bali A* - University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab Uni versity,*Corresponding India author: - - Alka Bali, Department of Pharmaceutical Chemistry, University In stitute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandi com garh,160014, India, Tel: 91-172-2541142; Fax: 91-172-541142; E-mail: alka.bali@rediffmail. Published Date: April 16, 2016 ABSTRACT Peptic ulcer disease is a widely prevalent upper gastrointestinal disorder worldwide. Gastric hypersecretion is recognized as the prime underlying cause of this disease. Earlier approaches towards alleviation of this disease have primarily focussed on symptomatic treatment of gastric hypersecretion with anti-secretory agents. Histamine H2 successful mechanistic intervention with acid hypersecretion and the prototypic drug cimetidine receptor antagonists represented the first earned the title of ‘first blockbuster drug’ due to its stupendous sales. Cimetidine, ranitidine2 and famotidine remained as first-line therapy for peptic ulcer disease for a very long time. H +/K + receptor antagonists had some limitations such as, ineffective daytime acid control, development of tolerance during therapy and acid rebound. Identification of the proton pump, H -ATPase, as final source of gastric acid secretion led to development of another novel class of antisecretory acid suppression compared to the H agents, termed as proton pump inhibitors2 (PPIs). These agents gave more potent and reproducible Peptic Ulcer Disease | www.smgebooks.com receptor antagonists and soon became first line drugs1 Copyright Bali A.This book chapter is open access distributed under the Creative Commons Attribution 4.0 International License, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ranitidine 150 mg/10 ml Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ranitidine Hydrochloride 167.5mg/10ml (equivalent to Ranitidine 150mg/10ml) Ethanol = 810mg/10ml Sorbitol = 1.4g/10ml Sodium = 22 mg/10 ml For full list of excipients see Section 6.1 3 PHARMACEUTICAL FORM Oral Solution A straw coloured liquid with odour of mint 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Ranitidine is indicated for the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. In addition, ranitidine is indicated for the prevention of NSAID (including aspirin) associated duodenal ulcers. Ranitidine is also indicated for the treatment of post-operative ulcer, Zollinger-Ellison Syndrome and treatment of oesophageal reflux disease including prevention of relapse. Ranitidine is indicated for the following conditions where reduction of gastric secretion and acid output is desirable; - the prophylaxis of gastro-intestinal haemorrhage from stress ulceration in seriously ill patients - the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers - before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson’s Syndrome), particularly obstetric patients during labour. Children (3 to 18 years) - Short term treatment of peptic ulcer - Treatment of gastro-oesophageal reflux, including reflux oesophagitis and symptomatic relief of gastro-oesophageal reflux disease. See section 4.4. Special warnings and precautions for use. 4.2 Posology and method of administration Posology Adults (including the elderly): Treatment of duodenal and gastric ulcer: The usual dosage is 150mg twice daily, taken in the morning and evening or a single bedtime dose of 300mg.
    [Show full text]
  • Histamine H2-Antagonists, Proton Pump Inhibitors and Other Drugs That Alter Gastric Acidity
    Jack DeRuiter, Principles of Drug Action 2, Fall 2001 HISTAMINE H2-ANTAGONISTS, PROTON PUMP INHIBITORS AND OTHER DRUGS THAT ALTER GASTRIC ACIDITY I. Introduction Peptide ulcer disease (PUD) is a group of upper gastrointestinal tract disorders that result from the erosive action of acid and pepsin. Duodenal ulcer (DU) and gastric ulcer (GU) are the most common forms although PUD may occur in the esophagus or small intestine. Factors that are involved in the pathogenesis and recurrence of PUD include hypersecretion of acid and pepsin and GI infection by Helicobacter pylori, a gram-negative spiral bacterium. H. Pylori has been found in virtually all patients with DU and approximately 75% of patients with GU. Some risk factors associated with recurrence of PUD include cigarette smoking, chronic use of ulcerogenic drugs (e.g. NSAIDs), male gender, age, alcohol consumption, emotional stress and family history. The goals of PUD therapy are to promote healing, relieve pain and prevent ulcer complications and recurrences. Medications used to heal or reduce ulcer recurrence include antacids, antimuscarinic drugs, histamine H2-receptor antagonists, protective mucosal barriers, proton pump inhibitors, prostaglandins and bismuth salt/antibiotic combinations. A characteristic feature of the stomach is its ability to secrete acid as part of its involvement in digesting food for absorption later in the intestine. The presence of acid and proteolytic pepsin enzymes, whose formation from pepsinogen is facilitated by the low gastric pH, is generally assumed to be required for the hydrolysis of proteins and other foods. The acid secretory unit of the gastric + + mucosa is the parietal (oxyntic) cell.
    [Show full text]
  • Making Health Care Safer: a Critical Analysis of Patient Safety Practices
    Evidence Report/Technology Assessment Number 43 Making Health Care Safer: A Critical Analysis of Patient Safety Practices Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2101 East Jefferson Street Rockville, MD 20852 www.ahrq.gov Contract No. 290-97-0013 Prepared by: University of California at San Francisco (UCSF)–Stanford University Evidence-based Practice Center Editorial Board Kaveh G. Shojania, M.D. (UCSF) Bradford W. Duncan, M.D. (Stanford) Kathryn M. McDonald, M.M. (Stanford) Robert M. Wachter, M.D. (UCSF) Managing Editor Amy J. Markowitz, JD Robert M. Wachter, MD Project Director Kathryn M. McDonald, MM UCSF–Stanford EPC Coordinator AHRQ Publication 01-E058 July 20, 2001 (Revised printing, indexed) ii Preface The Agency for Healthcare Research and Quality (AHRQ), formerly the Agency for Health Care Policy and Research (AHCPR), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments. To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation.
    [Show full text]
  • Inverse Agonism of Histamine H2 Antagonists Accounts for Upregulation of Spontaneously Active Histamine H2 Receptors MARTINE J
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 6802-6807, June 1996 Pharmacology Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active histamine H2 receptors MARTINE J. SMIT*, ROB LEURSt, ASTRID E. ALEWIJNSE, JOERI BLAUW, GERARD P. VAN NIEuw AMERONGEN, YVONNE VAN DE VREDE, EDWIN ROOVERS, AND HENK TIMMERMAN Leiden/Amsterdam Center for Drug Research, Department of Pharmacochemistry, Division of Medicinal Chemistry, Faculty of Chemistry, Vrije Universiteit, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands Communicated by James Black, King's College, London, United Kingdom, February 29, 1996 (received for review December 18, 1995) ABSTRACT Histamine H2 receptors transfected in Chi- withdrawal (21), and the development of tolerance (2, 5, 19, 23, nese hamster ovary (CHO) cells are time- and dose- 24). Coruzzi and Bertaccini (22) and Nwokolo et al. (21) dependently upregulated upon exposure to the H2 antagonists hypothesized that these observations could be explained by an cimetidine and ranitidine. This effect appears to be H2 recep- upregulation of H2 receptors. So far no data on the regulation tor-mediated as no change in receptor density was observed of H2 receptor expression by H2 receptor antagonists have after H1 or H3 antagonist treatment or after incubation with been presented, however. the structural analogue ofcimetidine, VUF 8299, which has no Studies examining the molecular mechanism underlying H2 H2 antagonistic effects. By using transfected CHO cells ex- receptor function have been greatly facilitated by the cloning pressing different densities of wild-type H2 receptors or an of the genes encoding the histamine H2 receptor (25-28). uncoupled H2Leut24Ala receptor, the histamine H2 receptor Model systems, expressing a homogeneous population of was found to display considerable agonist-independent H2 (mutant) H2 receptors, are currently available for studies receptor activity.
    [Show full text]